Nolan Sean P. 4
4 · Taysha Gene Therapies, Inc. · Filed Jan 4, 2024
Insider Transaction Report
Form 4
Nolan Sean P.
DirectorChief Executive Officer
Transactions
- Award
Employee Stock Option (right to buy)
2024-01-02+1,184,688→ 1,184,688 totalExercise: $1.71Exp: 2034-01-02→ Common Stock (1,184,688 underlying) - Award
Common Stock
2024-01-02+1,184,688→ 1,185,858 total
Holdings
- 1,535,545(indirect: See Footnote)
Common Stock
Footnotes (3)
- [F1]Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.
- [F2]The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.
- [F3]25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.